
Among other things, the need for extra funding for a phase III study with Diamyd Medical's diabetes vaccine candidate has made the Swedish company carry out a directed share issue.
The equity issuance, which has raised USD 17.5m (DKK 110m) for the company, targeted several institutional investors as well as qualified private investors in Sweden.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app